N-Desmethyltamoxifen, the major metabolite of Tamoxifen in humans and a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen, also is a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation.
[1] Vertosick FT Jr, et al. J Neurooncol. 1994;19(2):97-103. [2] Morad SA, et al. Biochim Biophys Acta. 2015 Jul;1851(7):919-28.
















